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ABSTRACT 21
Many animal species, including macropods, have the potential to act as atypical reservoirs of the  22
causative agent of Q fever, Coxiella burnetii. The objective of this study was to determine the  23
seroprevalence of C. burnetii in various macropod species in Australia. Competitive and indirect  24
ELISAs were developed for the testing of macropod sera for antibodies to phase II and I C. burnetii 25
antigens separately. A total of 500 macropod serum samples from selected species sampled in eastern  26
and western coastal states of Australia were screened for the presence of anti-C. burnetii antibodies.  27
An overall seroprevalence of 20.8% (95% CI 20.8-20.9%) was observed with 30.4% (30.2-30.9%) in  28
northern Queensland, 13.0% (12.9-13.1%) in southern Queensland, 7.1% (7.1-8.0%) in western  29
Queensland and 22.8% (22.7-22.9%) in south-western Western Australia. These data indicated  30
macropods represented a potential reservoir for zoonotic transmission of C. burnetii to domestic  31
animals and the human population. 32
33
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INTRODUCTION 37
Coxiella burnetii is an obligate intracellular pathogen with worldwide distribution and a wide host  38
range (Babudieri, 1959). In the natural lifecycle of the organism, it is transmitted between wild  39
animals and their ticks. Many serological surveys and bacterial isolations have indicated the extent of  40
wildlife coxiellosis worldwide. In Australia, bandicoots (Smith and Derrick, 1939; Smith 1942) and  41
macropods (Pope et al., 1960; Banazis et al., 2010) have been identified as potential reservoirs.  42
Macropods are marsupials belonging to the Family Macropodidae, which includes kangaroos,  43
wallabies, pademelons and bettongs. The bacterium can also be transmitted to livestock and other  44
domestic animals via ticks. Once in livestock, C. burnetii primarily infects the female reproductive  45Page 3 of 22
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tract, resulting in the shedding of a spore-like form of the organism in parturient fluids and milk  46
(Lang, 1990). Q fever is more commonly contracted following exposure to infected livestock such as  47
cattle, sheep and goats. Studies conducted in Queensland found many Q fever patients had no known  48
contact with the typical animal reservoirs. Two patients reported contact with wallabies (Chong et al.,  49
2003; Gale et al., 2007).  50
In Q fever patients, seroconversion to the various antigens post-infection is relatively well  51
characterised, with an initial rise in antibodies to phase II antigen generally followed by antibodies to  52
phase I antigen (Maurin and Raoult, 1999). Differences in titres of immunoglobulin isotypes to phase  53
II or phase I antigens also form the basis for diagnosis of acute or chronic Q fever. Antibodies to  54
phase II and I antigen of IgM isotype, and antibodies to phase II of IgG and IgA isotypes are  55
associated with acute Q fever; whereas, antibodies to phase I of IgG and IgA isotypes are associated  56
with chronic Q fever (Capo et al., 1998; Fournier and Raoult, 1999; Camacho et al., 2000). However,  57
the process of seroconversion is not well characterised in animals and seropositivity to either or both  58
antigenic phase of C. burnetii has been shown to vary between species (Enright et al., 1971; Marrie et  59
al., 1985; Marrie et al., 1993). Some studies have suggested the presence of antibodies to phase II  60
antigen in animal sera is indicative of recent infection (Lackman et al., 1962; Sidwell and Gebhardt,  61
1962). The current study aimed to determine the potential for native Australian macropods to act as  62
reservoirs of Q fever in Australia using two ELISA methods for the detection of antibodies to C.  63
burnetii in macropod sera.  64
65
MATERIALS AND METHODS 66
Sample collection 67
Study populations 68
A list of species sampled, numbers and common names is included in Table 1. A breakdown of study  69
populations, including species, region and sample methods is included in Table 2. Samples collected  70Page 4 of 22
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within southern Queensland originated from properties at three sites, including Warwick, Injune and  71
Roma. Samples collected within northern Queensland originated from properties at three sites,  72
including Townsville, Greenvale and Richmond. Samples collected within western Queensland  73
originated from properties at three sites, including Longreach, Thurles Park and Winton. A number of  74
samples from Townsville and western Queensland were donated from a serum bank for an unrelated  75
study and capture dates were not available. Samples collected within south-western Western Australia  76
originated from properties at five sites including Whiteman Park, Preston Beach, Capel, Nannup and  77
Eneabba. Site, species, sex and age data for each animal sampled were recorded. Sites included in the  78
survey are shown in Supplementary Figure 1. 79
80
Trapping 81
Trapped animals were captured according to procedures used by the Queensland Parks and Wildlife  82
Service using Treadle traps lined with foam and shade cloth.   All care was taken to reduce stress on  83
the animals. Blood samples (equivalent to less than 0.5% of the body weight to a maximum 2 mL)  84
collected from each identified animal were taken the lateral coccygeal vein of the tail with the animal  85
manually restrained in a Hessian sack. Following blood collection, animals were released at the site at  86
which they were captured. Whole blood was collected in a clot activating tube and centrifuged at  87
1,400 ×g for 10 min at 4°C. Serum removed from the samples was frozen at -20°C prior to analysis. 88
89
Post mortem 90
Blood samples were collected via cardiac puncture from animals shot by licensed kangaroo shooters  91
during routine culling expeditions. Harvesters held a commercial wildlife harvesting licence. Serum  92
was separated from whole blood and stored as described previously for trapped animals. 93
94
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Antigen was prepared according to the protocol described in the Manual of Diagnostic Tests and  96
Vaccines for Terrestrial Animals (OIE, 2004). Both phase I and phase II C. burnetii antigen were  97
produced using an Australian C. burnetii isolate (Cumberland strain). This isolate was obtained from  98
the Australian Rickettsial Reference Laboratory (Geelong, Victoria), which was isolated from a  99
patient who contracted Q fever through contact with beef cattle.  Phase II C. burnetii was obtained by  100
serial passage in vero cell culture to a total of 15 passages. Cell suspensions and supernatants were  101
pooled and centrifuged at 1,000 ×g at 20°C for 10 min. Supernatants were discarded and the cells  102
resuspended in PBS, pH 7.4. Host cells were disrupted by sonication and bacteria were separated from  103
cell debris by centrifugation at 550 ×g at 20°C for 10 min. The resultant supernatant was layered over  104
25% sucrose and centrifuged at 4,500 ×g at 20°C for 20 min. The supernatant was discarded and the  105
purified C. burnetii resuspended in PBS, pH 7.4. The bacteria were inactivated with 1% formalin for  106
48 hrs at 4°C, pelleted at 10,000 ×g at 20°C for 10 min and washed three times. The inactivated cells  107
were resuspended in sterile ddH2O. 108
109
Phase I C. burnetii antigen was produced via animal passage in A/J mice (Inbred albino: Tyr
c, Tyrp1
b,  110
a, Cdh23
ahl, H-2
a) followed by a single passage in the yolk sac of embryonated chicken eggs. Mice  111
were inoculated with 1×10
4 C. burnetii intra peritoneal and maintained for 7 days at which time the  112
spleens were removed for bacterial extraction as described above for phase II antigen. Bacteria were  113
separated from egg yolk and formalin-inactivated as described above for phase II antigen. 114
115
Phase II and I antigenicity was confirmed by complement block titration using commercial anti-C.  116
burnetii phase II and I control sera and antigens (Virion/Serion, Germany). Commercially available  117
phase II and I C. burnetii antigen and control sera (Virion\Serion, Germany) was initially used for  118
comparison and standardisation of the whole cell antigen. Absorbance values for control sera against  119
commercial antigen were comparable to those obtained with control sera against prepared whole cell  120
antigen. Both the competitive and indirect ELISAs were initially optimised and validated using serum  121Page 6 of 22
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from mice experimentally infected with C. burnetii and PBS inoculated negative controls. A total of  122
30 macropod samples were randomly selected and screened using reagent concentrations determined  123
using murine optimisation to indentify C. burnetii-positive and negative samples for subsequent use  124
as control sera. Positive thresholds were validated against murine and canine C. burnetii-positive and  125
negative sera. 126
127
Competitive ELISA 128
NUNC™ 96-well Maxisorp plates were coated with 50 µL of phase II or phase I antigen at 25 µg mL
- 129
1 in carbonate/bicarbonate coating buffer, pH 9.0 and incubated overnight at 37°C. Plates were coated  130
with 50 µL post-coating buffer (Tropbio, Australia), incubated at room temperature for 2 hr then  131
dried. Test sera were applied at a dilution of 1:10 in 50 µL aliquots in duplicate and incubated at 37°C  132
for  1  hr.  Positive  and  negative  control  sera  were  also  included  in  duplicate.  Indicator  serum  133
(previously defined, C. burnetii-positive bovine sera) was then applied at a dilution of 1:200 for both  134
antigenic phases and incubated at 37°C for a further 1 hr. The wells were washed three times with  135
PBS-T after which 50 µL horse-radish peroxidase (HRP)-conjugated rabbit anti-bovine Ig (Serotec,  136
UK) at 1:1,000 was applied and incubated at 37°C for 1 hr. The wells were washed again, after which  137
50 µL 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS) was applied and incubated at  138
37°C for 30 min. Optical density readings were obtained using a Multiskan Ascent plate reader at  139
414/494 nm. A reduction in optimal density of ≥ 70% from that of the indicator serum alone was  140
considered to be a positive result. Results of duplicates for each sample were averaged to produce a  141
mean result for each animal. A diagrammatic representation of the competitive ELISA is included in  142
Figure 1. A distribution of optical density values for the cELISA is included in Supplementary Figure  143
2. 144
145
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Indirect ELISA 147
NUNC™ 96-well Maxisorp plates were coated with phase II or phase I antigen and stabilised as  148
described previously for the competitive ELISA (cELISA). Test sera were applied at a dilution of  149
1:100 in 50 µL aliquots in duplicate and incubated at 37°C for 1 hr. Positive and negative control sera  150
were also included in duplicate. The wells were washed three times with PBS-T after which 50 µL of  151
chicken anti-macropod IgG polyclonal antibody (in-house production) was applied at a dilution of  152
1:250 for both antigenic phases and incubated at 37°C for a further 1 hr. The wells were then washed  153
four times with PBS-T after which 50 µL HRP-conjugated rabbit anti-chicken IgY (Jackson, USA) at  154
1:2,000 was applied and incubated at 37°C for 1 hr. The wells were washed again, after which 50 µL  155
ABTS was applied and incubated at 37°C for 30 min. Optical density readings were obtained using a  156
Multiskan Ascent plate reader at 414/494 nm. The Sample/Positive Ratio (S/P%) was calculated for  157
each sample using the following formula: S/P% = (OD sample – OD negative control) ÷ (OD positive  158
control  – OD negative control) × 100. Sera with an S/P% less than 50% were considered to be  159
negative. Samples with an S/P% of between 50% and 75% were considered to be positives; those  160
greater  than  75%  were  considered  strongly positive.  Results  of  duplicates  for  each sample were  161
averaged to produce a mean result for each animal. A diagrammatic representation of the indirect  162
ELISA is included in Figure 1. A distribution of optical density values for the cELISA is included in  163
Supplementary Figure 2. Chicken anti-macropod IgG polyclonal antibodies were produced following  164
immunization of white leghorn chickens with purified macropod IgG according to standard protocols. 165
166
Statistical analyses 167
Percentage seropositivity was calculated by dividing the number of positive samples by the total  168
number of samples and multiplying by 100. Comparison of seropositivity between sites and regions  169
was performed using single factor ANOVA tests. Agreement between (cELISA and iELISA) and  170
within ELISAs (Phase II and Phase I) was determined by kappa measurement of agreement. A kappa  171
(K)  value  of  1  indicates  perfect  agreement  and  a  value  of  0  indicates  no  agreement.  Excellent  172Page 8 of 22
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agreement is indicated by values greater than 0.75, fair to good agreement by values of 0.4-0.75 and  173
poor agreement by values less than 0.4.  174
175
An ordinal logistic generalised linear model was constructed using SPSS Statistics 19 (IBM, USA) to  176
identify factors associated with seropositivity for each antigenic phase separately, and seropositivity  177
to either or both antigens combined in macropod samples. All data was transformed into numerical  178
values prior to statistical analysis. Type III analysis was performed with Wald Chi-Square test and  179
95% Profile Likelihood Confidence Intervals calculated. Factors modelled included, sex, age, species,  180
sample site and region. Age was subjectively categorised as adult (approximately three years and  181
older)  or  juvenile  (under  three  years  including  pouch young)  based  on size and apparent  sexual  182
maturity. Species were categorised according to phylogenetic similarity and were divided into genera  183
and  sub-genera  (Table  1).  The  eastern  grey  kangaroo  (Macropus  giganteus)  and  western  grey  184
kangaroo  (Macropus  fuliginosus)  samples  were  considered  separately  despite  their  phylogenetic  185
similarity due to the geographical separation of these species. Sample sites were grouped according to  186
statistical division (region), with each site defined as within a 100 km radius of the major locality in  187
the area.  188
189
RESULTS 190
The current study demonstrated that the seroprevalence of C. burnetii in the macropod populations  191
sampled from southern Queensland (n=200), northern Queensland (n=120), western Queensland (n =  192
28) and southern Western Australia (n=180) were 13.0% (95% CI 12.9-13.1%), 30.4% (95% CI 30.2- 193
30.9%), 3.6% (95% CI 3.6-4.3%) and 22.8% (95% CI 22.7-22.9%) respectively. Overall  194
seroprevalence in the 500 macropod samples tested was 20.8% (95% CI 20.8-20.9%). Sites with  195
significantly higher seroprevalence included Greenvale and Richmond in northern Queensland with  196
58.8% (95% CI 56.9-63.6%), and 46.2% (95% CI 44.7-51.9%) respectively and Capel and Whiteman  197Page 9 of 22
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Park in southern Western Australia with 43.2% (95% CI 42.5-44.9%) and 37.5% (95% CI 36.8- 198
39.3%) respectively. 199
200
Reactivity to phase II and phase I antigens in serum samples varied both within and between the two  201
ELISA methods performed. The number of samples determined to be positive for antibodies to both  202
phase II and phase I antigens varied between sites and regions (Table 3). The number of samples  203
determined to be positive for antibodies against either or both phase II and phase I using the different  204
ELISA methods also varied between sites and regions (Table 3). Reactivity to phase II and phase I  205
antigens in serum samples varied according to species and site (Table 4). Species with relatively high  206
seroprevalence included M. giganteus, M. fuliginosus, M. robustus and M. dorsalis (Table 4). 207
However, seroprevalence varied between sites for the same species. 208
209
Despite variable kappa agreement within each ELISA method, good agreement was found between  210
phase II and I seropositivity using the competitive ELISA (cELISA) (K<0.6) and fair agreement using  211
the polyclonal indirect ELISA (iELISA) (K>0.4). Overall, 43.2% of macropod samples testing  212
positive for antibodies to phase II antigen, also tested positive for phase I antigen. This differed by  213
region, with 64.3% of samples positive for phase II antigen also reacting against phase I antigen in the  214
northern Queensland samples and 57.7%  in southern Queensland samples, with only 19.5% of  215
samples from Western Australia and 0% of western Queensland samples reacting against both  216
antigens. Kappa measurement of agreement between ELISA methods was minimal, with only 7 of the  217
500 samples (1.4%) determined to be positive using both ELISA methods (K<0.4). Overall  218
seropositivity in macropod samples in the various regions tested, as determined using both ELISA  219
methods is displayed in Table 3. 220
221Page 10 of 22
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Statistically significant factors associated with seropositivity to phase II antigen using both ELISAs  222
included Sex (P<0.05), Site (P<0.01) and Region (P<0.01) with male animals, animals from  223
Greenvale, Whiteman Park and animals from northern Queensland  found more likely to be positive  224
(Table 5). Both site and region were significantly associated with seropositivity to phase I antigen  225
using both ELISAs (P<0.01). Specifically, animals from Richmond, Greenvale and animals from  226
northern Queensland were found more likely to be positive (Table 5). Statistically significant factors  227
associated with seropositivity to either or both C. burnetii antigens were similar to those for each  228
antigen individually. These factors included Site (P<0.01) and Region (P<0.01). Within these it was  229
found that animals from Greenvale, Capel, Whiteman Park and animals from northern Queensland  230
were more likely to have antibodies to C. burnetii (Table 5). No significant associations were found  231
between seropositivity and age or species. 232
233
DISCUSSION 234
Seropositivity rates found in the current study are similar to those reported in previous studies in  235
Queensland (Pope et al., 1960) and Western Australia (Banazis et al., 2010). Several sites were found  236
to have higher than expected numbers of seropositive macropods. These included Greenvale (QLD),  237
Richmond (QLD), Capel (WA) and Whiteman Park (WA). Northern Queensland as a whole also had  238
higher than expected numbers of seropositive animals. The relatively high seroprevalence found at  239
Whiteman Park is noteworthy due to its location in an urban area. 240
241
Seropositivity  varied  for  phase  II  and  phase  I  antigens  depending  on  the  ELISA  method  used.  242
Combined  seropositivity  for  either  or  both  phase  II  and  I  antigens  also  varied  between  ELISA  243
methods. In the current study, seropositivity was generally higher for phase II antigen than phase I  244
antigen, with the exception of the northern Queensland macropod cohort.  245
246Page 11 of 22
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Seropositivity was similar for phase II and phase I antigen using the cELISA for all species tested,  247
with many of these samples testing positive for both antigens (K=0.6). This ELISA method also  248
resulted in the highest seropositivity values for the various species. The greater number of positive  249
samples detected by the cELISA is thought to be due to the choice of indicator sera and conjugate.  250
Strongly reacting bovine sera was used as the indicator, combined with anti-bovine Ig conjugate, as  251
bovine sera was found to have no cross-reactivity with the IgG of other species tested. As the  252
conjugate was not immunoglobulin isotype specific, it would be able to detect bovine  253
immunoglobulin of all potential isotypes. It is hypothesised that due to this factor, prevention of the  254
indicator sera from binding to C. burnetii antigens by the test sera would indicate the presence of any  255
potential immunoglobulin isotypes in the test sera. Immunoglobulin isotypes associated with Q fever  256
in human serology include IgM and IgG predominately, but also IgA (Angelakis and Raoult, 2010).  257
Therefore, it is thought that the seropositivity determined using the cELISA, may represent antibodies  258
to C. burnetii from these three immunoglobulin isotypes. However, the only antibodies that would be  259
detected in the test sera using cELISA are those that bind to the same epitopes in the antigen  260
preparation as the indicator sera. Conversely, it is thought that the positive samples detected by the  261
iELISA may mainly represent IgG1 antibody as this would have been the predominant isotype present  262
in the inoculum used to produce the polyclonal antibody. The poor kappa agreement between the  263
ELISA methods is also thought to be due to epitope differences, as IgG1 is protein specific and IgG2 264
carbohydrate specific. As whole cell antigen preparations were used in the ELISAs, both protein and  265
liopolysaccaride antigens would be present. 266
267
Two ELISA methods were developed for the detection of antibodies to C. burnetii in native  268
Australian marsupials. As can be seen in the current study, the choice of ELISA method and  269
conjugate greatly affects the detection of antibodies. Antibody responses to C. burnetii in the animals  270
tested were highly heterogeneous, a finding which was consistent with human Q fever serology. A  271
similar discrepancy in the estimation of seroprevalence in a population was demonstrated in a recent  272
human study using two different serological assays (Blaauw et al., 2011). The heterogeneity of the  273Page 12 of 22
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antibody response to C. burnetii infection complicates serological investigation and epidemiological  274
studies. The development of diagnostic tests for native wildlife is complicated by a lack of diagnostic  275
reagents for these animals. In serosurveys, the cELISA developed in the current study would be of  276
greatest advantage, whereas, in isotype specific studies the iELISA may be of greater worth. Further  277
work would be required in animal serology in order to determine the pattern of antibody production in  278
response to C. burnetii. Such patterns may differ between species and may indicate relative recentness  279
of infection and whether animals are chronically infected. Additional work would also be required to  280
establish the identity of the immunoglobulin subsets detected in the current study, as isotype-specific  281
and subclass-specific regents are not currently available for native Australian marsupials. However,  282
this work would require the experimental infection of Australian native marsupials with C. burnetii, a  283
process that is unlikely to be approved under existing animal ethics regulations. Ultimately, the aim of  284
this project was to detect circulating antibodies to C. burnetii in native Australian marsupials and the  285
subsequent detection of antibodies of multiple isotypes and subclasses, while confusing, provides  286
evidence of prior infection with C. burnetii in these species. 287
288
In conclusion, it was found that antibodies to C. burnetii were detected in all native macropod species  289
tested in this study. This result indicates these animals are potential and highly probable reservoirs of  290
C. burnetii. The increasing incidence of human Q fever cases where no contact with more typical  291
reservoir species is present may be attributable to contact with atypical reservoirs, such as marsupials.  292
Housing shortages in Queensland have resulted in residential areas expanding into wildlife habitats  293
throughout the State. There has also been an increase in demand for semi-rural housing estates in  294
northern Queensland. These developments would increase the exposure of the human population and  295
companion animals to wildlife. The close association these species have with human habitation,  296
combined with the evidence of exposure to C. burnetii may have important public health implications.  297
298
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379
Figure 1: Diagrammatic representation of the competitive (cELISA) and indirect (iELISA)  380
ELISAs developed for the screening of macropod sera for antibodies to Coxiella burnetii. 381
382
Suppl Figure 1: Origin of macropod samples included in the survey 383
384
Suppl Figure 2: Distribution of optical density values for phase II and phase I ELISAs using  385
both ELISA methods. [A] Competitive ELISA, [B] Indirect ELISA. 386
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Table 1: Macropod species included in the survey and common names 414
GROUP SPECIES INCLUDED NUMBER
Subgenus Notamacropus Macropus agilis (Agile wallaby)
Macropus dorsalis (Black-striped wallaby)
Macropus rufogriseus (Red-necked wallaby)
Macropus parryi  (Whiptail wallaby)
21
10
9
2
Subgenus Osphranter Macropus robustus (Common wallaroo)
Macropus rufus (Red kangaroo)
Macropus antilopinus (Antilopine kangaroo)
16
12
9
Subgenus Macropus 1 Macropus giganteus (Eastern grey kangaroo) 164
Subgenus Macropus 2  Macropus fuliginosus (Western grey kangaroo) 180
Genus Petrogale Petrogale penicillata (Brush-tailed rock wallaby) 68
Genus Thylogale Thylogale stigmatica (Red-legged pademelon) 5
Genus Aepyprymnus Aepyprymnus rufescens (Rufous bettong) 4
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419
Table 2: Macropod species and sites included in the survey 420
SITE SPECIES
SAMPLES
(n)
SAMPLE 
METHOD
Southern Queensland M. giganteus 114 p.m.
P. penicillata 64 trap
M. robustus 13 p.m.
M. rufogriseus 9 trap
Northern Queensland M. giganteus 30 p.m.
M. agilis 21 p.m.
M. antilopinus 9 p.m.
M. dorsalis 9 trap
M. rufus 5 p.m.
T. stigmatica 5 trap
P. penicillata 4 trap
A. rufescens 4 trap
M. robustus 3 p.m.
M. parryi 2 trap
Western Queensland M. giganteus 20 p.m.
M. rufus 7 p.m.
M. dorsalis 1 trap
Western Australia M. fuliginosus 180 p.m.
nbp.m. represents post mortem sampling 421Page 19 of 22
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Table 3: Seroprevalence of anti-Coxiella burnetii antibodies in macropods using two ELISA methods 422
SEROPREVALENCE % (95%CI)
PHASE II  PHASE I  PHASE II AND/OR I
REGIONS
SITES
SAMPLES
(n)
cELISA iELISA BOTH cELISA iELISA BOTH cELISA iELISA BOTH
Southern Queensland (SQ)
(Warwick, Injune, Roma)
200
8.0
(7.9-8.1)
5.5
(5.5-5.6)
13.0
(12.9-13.1)
6.5
(6.3-6.6)
1.0
(1.0-1.0)
7.5
(7.5-7.6)
8.5
(7.5-9.5)
5.5
(5.5-5.6)
13.0
(12.9-13.1)
Northern Queensland (NQ)
(Townsville, Greenvale, Richmond)
92
16.3
(16.2-16.6)
7.6
(7.6-7.8)
21.7
(21.6-22.1)
20.7
(20.5-21.0)
9.8
(9.7-10.0)
28.3
(28.0-31.2)
22.8
(22.7-23.2)
10.9
(10.8-11.1)
30.4
(30.2-30.9)
Western Queensland (WQ)
(Longreach, Thurles Park, Winton)
28
0.0
(0.0-0.4)
3.6
(3.6-4.3)
3.6
(3.6-4.3)
0.0
(0.0-0.4)
0.0
(0.0-0.4)
0.0
(0.0-0.4)
0.0
(0.0-0.4)
3.6
(3.6-4.3)
3.6
(3.6-4.3)
South-western Western 
Australia (WA)
(Preston Beach, Capel, Nannup, 
Whiteman Park, Eneabba) 
180
8.3
(8.3-8.4)
16.8
(16.6-16.8)
17.8
(17.7-17.9)
5.0
(5.0-5.1)
5.0
(5.0-5.1)
9.4
(9.4-9.5)
11.7
(11.6-11.8)
18.4
(18.3-18.5)
22.8
(22.7-22.9)
Total
500
9.2
(9.19-9.22)
9.8
(9.79-9.83)
15.8
(15.77-15.84)
8.2
(8.19-8.22)
4.0
(4.0-4.01)
11.6
(11.58-11.63)
9.8
(9.79-9.83)
11.0
(10.98-11.03)
20.8
(20.8-20.9)
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Table 4: Seroprevalence of anti-C. burnetii antibodies in macropod species sampled 427
SITE SPECIES
SAMPLES
(n)
POSITIVE
(n)
SEROPREVALENCE
(95% CI)
Warwick (SQ) P. penicillata 64 7 10.9% (10.9-11.3%)
M. robustus 13 3 23.1% (22.7-27.2%)
M. rufogriseus 9 0 0.0%   (0-3.8%)
M. giganteus 8 2 25.0% (24.6-33.1%)
Injune (SQ) M. giganteus 83 12 14.5% (14.4-14.7%)
Roma (SQ) M. giganteus 23 2 8.7%   (8.6-9.9%)
Townsville (NQ) M. agilis 16 1 6.3%   (6.2-8.1%)
M. giganteus 13 5 38.5% (37.4-43.7%)
M. antilopinus 9 1 11.1% (11.1-16.4%)
M. dorsalis 8 2 25.0% (24.6-33.1%)
T. stigmatica 5 2 40.0% (38.9-57.0%)
P. penicillata 4 0 0.0%   (0.0-15.1%)
A. rufescens 4 0 0.0%   (0.0-15.1%)
M. parryi 2 0 0.0%   (0.0-42.1%)
Richmond (NQ) M. giganteus 5 2 40.0% (38.9-57.0%)
M. rufus 5 1 20.0% (19.9-34.3%)
M. robustus 3 2 66.7% (63.5-99.7%)
M. dorsalis 1 1 100% (97.5%-100%)
Greenvale (NQ) M. giganteus 12 7 58.3% (56.0-65.4%)
M. agilis 5 3 60.0% (57.1-78.9%)
Longreach (WQ) M. giganteus 17 1 5.9%   (5.9-7.6%)
M. dorsalis 1 0 0.0%   (0.0-97.5%)
Thurles park (WQ) M. rufus 7 0 0.0%   (0.0-5.9%)
M. giganteus 1 0 0.0%   (0.0-97.5%)
Winton (WQ) M. giganteus 2 0 0.0%   (0.0-42.1%)
Preston Beach (WA) M. fuliginosus 60 10 16.7% (16.5-17.2%)
Capel (WA) M. fuliginosus 37 16 43.2% (42.5-44.9%)
Nannup (WA) M. fuliginosus 34 3 8.8%   (8.8-9.5%)
Whiteman Park (WA) M. fuliginosus 32 12 37.5% (36.8-39.3%)
Eneabba (WA) M. fuliginosus 17 0 0.0%   (0.0-1.1%)
428
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Table 5: Factors associated with seropositivity to C. burnetii in macropods 430
FACTOR Risk Ratio Odds Ratio P
SEROPOSITIVITY TO PHASE II ANTIGEN
Greenvale origin 2.7 3.9 <0.05
Whiteman Park origin 2.3 3.0 <0.05
Northern Queensland origin 1.5 1.6 <0.01
Male 1.5 1.6 <0.05
SEROPOSITIVITY TO PHASE I ANTIGEN
Greenvale origin 9.2 20.8 <0.01
Richmond origin 6.5 11.1 <0.05
Northern Queensland origin 7.7 10.3 <0.01
SEROPOSITIVITY TO EITHER/BOTH PHASE II/I ANTIGEN
Greenvale origin 3.4 6.8 <0.01
Capel origin 2.6 3.8 <0.05
Whiteman Park origin 2.1 2.8 <0.05
Northern Queensland origin 1.9 2.3 <0.01
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